CD4 and ovarian cancer: Pseudotime analysis showed that the transition of Th1 cells into CD4+ Tpex and CD4+ Ttex in mice with LLC or ovarian cancer was a dynamic process similar to that of CD8+ T cells, suggesting that RACIM can effectively reverse this transition.